View Future GrowthItem 9 Labs 과거 순이익 실적과거 기준 점검 0/6지난 몇 년간 Item 9 Labs 의 실적에 대한 데이터가 부족합니다.핵심 정보n/a순이익 성장률n/a주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트30 Jun 2023최근 과거 실적 업데이트공시 • Aug 04Item 9 Labs Corp. to Report Q3, 2022 Results on Aug 15, 2022Item 9 Labs Corp. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 15, 2022모든 업데이트 보기Recent updates공시 • Mar 25Item 9 Labs Corp. Declines Re-Election of Lisa Rejler as Board MemberItem 9 Labs Corp. announced that the Nomination Committee proposes that the Annual General Meeting shall re-elect the board members Peter Rejler, Jan Samuelsson, Patrik Boman, Peter Johansson and Susanne Blanke and that the General Meeting resolves on new election of Martina Rejler. The board member Lisa Rejler declines re-election, at the AGM to be held on April 24, 2025.공시 • Apr 11Item 9 Labs Corp., Annual General Meeting, May 16, 2024Item 9 Labs Corp., Annual General Meeting, May 16, 2024, at 14:00 Central European Standard Time. Location: Östra Hamngatan 52 Gothenburg Sweden Agenda: To consider Presentation of the annual financial report and the auditor's report, as well as the consolidated annual financial report, the consolidated auditor's report and the Board of Directors' report; to consider (a) the adoption of the income statement and the balance sheet and the consolidated income statement and the consolidated balance sheet as well as the Board of Directors report pursuant to Chapter 8, Section 53a of the Swedish Companies Act, (b) the disposition of the Company's funds according to the adopted balance sheet and (c) the discharge from liability for the members of the Board of Directors and the CEO; to consider the election of members of the Board of Directors and appointment of auditors and deputy auditors, if any; and to consider any other matters.공시 • Jul 23+ 1 more updateDouglas Bowden Resigned as Chairman of the Board of Directors of Item 9 Labs Corp, Effective July 18, 2023Douglas Bowden has resigned his positions as Chairman of the Board of Directors of Item 9 Labs Corp, effective July 18, 2023. The positions will be left vacant until further notice due to the receivership appointment.공시 • May 25Item 9 Labs Corp. Announces Management ChangesItem 9 Labs Corp. announced that Director Jeffrey Rassás has been appointed to Strategic Advisor and will be primarily driving investor & public relations as well as capital needs. Chris Wolven, current Chief Operating Officer, will now oversee all Company entities and operations and will be the primary Company-facing executive for Item 9 Labs Corp. Michael Keskey has resigned as Chief Legal Officer.공시 • May 23+ 1 more updateItem 9 Labs Corp. Announces CEO ChangesItem 9 Labs Corp. announced that on May 17, 2023, Mr. Michael Weinberger voluntarily resigned as Chief Executive Officer and member of the Board of Directors of the Company. On May 22, 2023, the Board appointed Mr. Douglas Bowden, age 63, as the Company’s Interim Chief Executive Officer. Mr. Bowden is currently the Chairman of the Company’s Board of Directors. The biography for Mr. Bowden is set forth below: Mr. Bowden started his career in the electronics industry, working in a successful family run business, which he purchased with his brother and ran for nearly 20 years. This tech company's success was based on signal processing and monitoring providing hardware and software for broadcasters during the high definition revolution. Bowden sold his business in 2009 and in 2013, Mr. Bowden and his son started Viridis Group, a real estate company centered on residential remodeling, multifamily and commercial real estate development in Colorado and Arizona. Through this venture they gained experience in real estate acquisition, design, project and construction management, leasing, finance and sales. Viridis Group has recently adopted the name Bowden Investment Group. Mr. Bowden attended the University of South Dakota where he studied business. Mr. Bowden is co-founder of Viridis Group, dba Bowden Investment Group, a strategic partner of the Company.공시 • May 16Item 9 Labs Corp. announced delayed 10-Q filingOn 05/15/2023, Item 9 Labs Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 11Item 9 Labs Releases Latest Limited Edition One-Gram Rosin-Infused Pre-RollsItem 9 Labs announced the latest release of its limited edition one-gram rosin-infused pre-rolls in participating Arizona dispensaries. The product release follows a successful initial test run in December 2022 that immediately sold out after being stocked in local dispensaries and generated extremely positive customer and budtender feedback on the product quality. The demand for solventless cannabis products in Arizona has continued to grow since the start of the state's adult-use cannabis market, especially in the concentrate and vape categories. The niche sector provides a consistent, high quality and fuller expression of the various cannabinoids and terpenes that the cannabis plant has to offer. Cannabis data firm BDSA analyzed product data from the past year and noted that the growing rosin category is making a significant mark among many mature markets in the evolving industry, counting single to double-digit growth in sales from 2021 to 2022. Item 9 Labs' addition of rosin-infused pre therolls bolsters its already extensive product lineup of connoisseur grade pre-rolls, featuring one-gram pre-rolls crafted with its award-winning flower and infused with live resin sugar, live resin badder or crumble concentrates. According to BDSA's most recent market research, Item 9 Labs ranked No. 3 in Arizona's one-gram infused pre-roll category for February 2023, capturing 8.5% market share. Overall, the state generated $4.16 million in infused pre-rolls that month. Being sold in over 65% of Arizona's dispensaries, Item 9 Labs is recognized as one of the top 10 leading cannabis brands in the state. The rosin-infused pre -infused pre-rolls are sold at participating Botanica, JARS and Nature's Medicines locations, among other dispensaries throughout Phoenix.공시 • Dec 30Item 9 Labs Corp. announced delayed annual 10-K filingOn 12/29/2022, Item 9 Labs Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Dec 09Item 9 Labs Corp. Announces Management PromotionsItem 9 Labs Corp. announced promotion of Mark Busch, Senior Vice President of Corporate Development, Cory Carter, Senior Vice President of Cultivation and Jayne Levy Senior Vice President of Communications. Mark Busch is One of the first hires on the Unity Rd. brand, Busch joined in 2018, pre-dating Item 9 Labs Corp.'s acquisition of Unity Rd.'s franchisor, OCG Inc. in 2021. He is responsible for overseeing merger and acquisition strategy and activities. He has led the team through acquisitions of multiple dispensaries and most recently, has been spearheading the Company's approaching acquisition of Sessions. Carter joined OCG Inc. in 2019 and took over all Item 9 Labs Corp. cultivation operations upon acquisition close. He is lead on all production, manufacturing and packaging of the Company's award-winning Item 9 Labs cannabis products, including managing a team of 50-plus and aiding in the continued development of the Company's cultivation and lab site in Coolidge, Ariz. Levy has been with Unity Rd. since the cannabis franchise's inception in 2018. She plays an integral role in the Company with a hand in all facets of communications – spearheading internal and corporate communications, investor relations, public relations and beyond.공시 • Dec 01+ 1 more updateItem 9 Labs Corp. Announces Resignation of Andrew Bowden as DirectorOn November 23, 2022, Mr. Andrew Bowden voluntarily resigned as Chief Executive Officer and member of the Board of Directors of Item 9 Labs Corp. The resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. The Company is appreciative of Mr. Bowden’s years of service to the Company as a director and Chief Executive Officer.공시 • Aug 04Item 9 Labs Corp. to Report Q3, 2022 Results on Aug 15, 2022Item 9 Labs Corp. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 15, 2022공시 • Jun 05Item 9 Labs Corp Announces Resignation of Jeffrey Rassas as the Chief Strategy OfficerOn June 1, 2022, Mr. Jeffrey Rassas resigned, effective immediately, as the Chief Strategy Officer of Item 9 Labs Corp. (the Company") and the Company's management accepted Mr. Rassas' resignation on June 1, 2022. Mr. Rassas' resignation was not due to any disagreement with the Company on any matter relating to the Company's operations, policies, practices, or otherwise. Mr. Rassas will remain on the Company's board of directors and will continue working with the Company in a consulting role.공시 • May 26Item 9 Labs Corp. (OTCPK:INLB) signed a definitive agreement to acquire Sessions Cannabis from Steven Fry, Najla Guthrie, Darryl Allen, Louis Laskovski, 2628146 Ontario Ltd. and 11949896 Canada Inc. for $21 million.Item 9 Labs Corp. (OTCPK:INLB) signed a definitive agreement to acquire Sessions Cannabis from Steven Fry, Najla Guthrie, Darryl Allen, Louis Laskovski, 2628146 Ontario Ltd. and 11949896 Canada Inc. for $21 million on May 18, 2022. As per the terms of the transaction, Item 9 Labs shall pay $12.8 million plus the earnout payments of $4.1 million of common stock 12 months following the closing date and $4.1 million common stock 24 months following the closing date subject to post-closing adjustments. Item 9 Labs Corp. shall pay a termination fee of $0.54 million to the sellers. The transaction is subject to customary closing conditions including Item 9 Labs receiving financing sufficient to complete the transaction and Sessions Cannabis shall have a minimum cash balance of $0.1 million. Frank Robinson and Jeffrey Mikelberg of Cassels Brock & Blackwell LLP acted as legal advisors to the sellers and Francesco Gucciardo and Gary Volman of Aird & Berlis LLP acted as legal advisor to Item 9 Labs Corp.공시 • Mar 06Item 9 Labs Corp. (OTCPK:INLB) acquired Certain Assets from Nebrina Adams County LLC.Item 9 Labs Corp. (OTCPK:INLB) agreed to acquire Certain Assets of Nebrina Adams County LLC for $2 million on October 6, 2021. The total purchase price will be payable as follows: (i) Upon conditional approvals of the change of ownership from state and local licensing authorities concerning the transfer of ownership of the Licenses from Seller to Buyer, Buyer shall deposit into an escrow account One Million US Dollars. ii) At the Closing, Buyer and Company shall execute and deliver to Seller an unsecured promissory note with a principal amount of Two Hundred Thousand US Dollars ($200,000.00), with an interest rate of five percent (5%) per annum simple interest, for a term of eighteen (18) full months commencing on the Closing Date, and payable in six (6) installments commencing on the last day of each three (3) month period following the Closing Date (the " Note " or " Promissory Note" ) until paid in full; and (iii) Buyer shall issue to the Seller Three Hundred Thousand (300,000) shares of PubCo's restricted common shares of the Company. The Shares shall be subject to a leak out agreement. Closing shall be contingent upon the unconditional approval by MED and the Local Licensing Authority of the Transactions. Jean Gonnell of Gonnell Law acted as legal advisor to Nebrina. Zuber Lawler & Del Duca LLP acted as legal advisor to Item 9. Item 9 Labs Corp. (OTCPK:INLB) acquired Certain Assets from Nebrina Adams County LLC on March 4, 2022.공시 • Mar 04Item 9 Labs Corp. Appoints Shane Evans to Its Board of DirectorsItem 9 Labs Corp. announced that Shane Evans, founder of Massage Heights, has been appointed to its Board of Directors.공시 • Feb 03Item 9 Labs Corp. Announces Resignation of Ronald L. Miller, Jr. from the Board of DirectorsOn January 25, 2022, Mr. Ronald L. Miller, Jr. resigned, effective immediately, from the board of directors of Item 9 Labs Corp. and the board accepted Mr. Miller’s resignation on January 26, 2022. Mr. Miller’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies, practices, or otherwise. The Company is appreciative of Mr. Miller’s decade of service to the Company as a director. Mr. Miller will continue working with the Company in a financial consulting role.공시 • Dec 31Item 9 Labs Corp. announced delayed annual 10-K filingOn 12/30/2021, Item 9 Labs Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Dec 30Item 9 Labs Corp. announced delayed annual 10-K filingOn 12/29/2020, Item 9 Labs Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Sep 26Item 9 Labs Corp. (OTCPK:INLB) entered into an agreement to acquire OCG Inc. for $36.6 million.Item 9 Labs Corp. (OTCPK:INLB) entered into an agreement to acquire OCG Inc. for $36.6 million on February 27, 2020. Under the terms of the transaction, Item 9 Labs Corp. will issue 30 million restricted shares as consideration to acquire 52.22 million shares of OCG Inc. resulting in an exchange ratio of 0.575 shares of Item 9 Labs Corp. for each share of OCG Inc. Upon closing, OCG Inc. will become a wholly-owned direct subsidiary of Item 9 Labs Corp. Upon closing of the transaction, OCG Inc. may nominate, and Item 9 Labs Corp. agrees to appoint, two persons designated by OCG Inc. to Item 9 Labs Corp.’s Board of Directors. The transaction is subject to the adoption of the agreement by the requisite vote of the stockholders of OCG Inc. and Item 9 Labs Corp., approval of the issuance of shares of Item 9 Labs Corp. as merger consideration, an appropriate level and Director and Officers Liability Insurance being in place, financing contingency that Item 9 Labs Corp. must raise approximately $2 million and delivery by OCG Inc. of copies of a lock up and leak out agreement. The Board of Directors of Item 9 Labs Corp. has approved the agreement and the transactions contemplated hereby. The transaction is expected to closing in early July 2020. The transaction is expected to close near the Item 9 Labs’s fiscal year end of September 30, 2020. Michael Weiner and David Mangum of Dorsey & Whitney LLP acted as legal advisors for OCG, Inc. Jessica M. Lockett of Horwitz +Armstrong acted as legal advisor for Item 9 Labs Corp.매출 및 비용 세부 내역Item 9 Labs가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:INLB 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Jun 2320-3118031 Mar 2320-3118031 Dec 2221-3119030 Sep 2222-3119030 Jun 2224-2219031 Mar 2226-1717031 Dec 2125-1315030 Sep 2122-1113030 Jun 2118-99031 Mar 2114-107031 Dec 2010-116030 Sep 208-126030 Jun 207-135031 Mar 206-126031 Dec 196-116030 Sep 195-105030 Jun 194-23031 Mar 193-22031 Dec 182-11030 Sep 181-11030 Sep 170000양질의 수익: INLB가 고품질 수익을 갖고 있는지 판단하기에는 데이터가 부족합니다.이익 마진 증가: 지난 1년 동안 INLB의 이익률이 개선되었는지 판단하기에 데이터가 부족합니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 INLB의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: INLB의 지난해 수익 성장률을 5년 평균과 비교하기에 데이터가 부족합니다.수익 대 산업: INLB의 지난 해 수익 증가율이 Pharmaceuticals 업계 평균을 상회했는지 판단하기에 데이터가 부족합니다.자기자본이익률높은 ROE: INLB는 현재 수익성이 없으므로 자본 수익률이 음수(0%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 10:12종가2026/05/11 00:00수익2023/06/30연간 수익2022/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Item 9 Labs Corp.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Joseph GomesNOBLE Capital Markets, Inc.
공시 • Aug 04Item 9 Labs Corp. to Report Q3, 2022 Results on Aug 15, 2022Item 9 Labs Corp. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 15, 2022
공시 • Mar 25Item 9 Labs Corp. Declines Re-Election of Lisa Rejler as Board MemberItem 9 Labs Corp. announced that the Nomination Committee proposes that the Annual General Meeting shall re-elect the board members Peter Rejler, Jan Samuelsson, Patrik Boman, Peter Johansson and Susanne Blanke and that the General Meeting resolves on new election of Martina Rejler. The board member Lisa Rejler declines re-election, at the AGM to be held on April 24, 2025.
공시 • Apr 11Item 9 Labs Corp., Annual General Meeting, May 16, 2024Item 9 Labs Corp., Annual General Meeting, May 16, 2024, at 14:00 Central European Standard Time. Location: Östra Hamngatan 52 Gothenburg Sweden Agenda: To consider Presentation of the annual financial report and the auditor's report, as well as the consolidated annual financial report, the consolidated auditor's report and the Board of Directors' report; to consider (a) the adoption of the income statement and the balance sheet and the consolidated income statement and the consolidated balance sheet as well as the Board of Directors report pursuant to Chapter 8, Section 53a of the Swedish Companies Act, (b) the disposition of the Company's funds according to the adopted balance sheet and (c) the discharge from liability for the members of the Board of Directors and the CEO; to consider the election of members of the Board of Directors and appointment of auditors and deputy auditors, if any; and to consider any other matters.
공시 • Jul 23+ 1 more updateDouglas Bowden Resigned as Chairman of the Board of Directors of Item 9 Labs Corp, Effective July 18, 2023Douglas Bowden has resigned his positions as Chairman of the Board of Directors of Item 9 Labs Corp, effective July 18, 2023. The positions will be left vacant until further notice due to the receivership appointment.
공시 • May 25Item 9 Labs Corp. Announces Management ChangesItem 9 Labs Corp. announced that Director Jeffrey Rassás has been appointed to Strategic Advisor and will be primarily driving investor & public relations as well as capital needs. Chris Wolven, current Chief Operating Officer, will now oversee all Company entities and operations and will be the primary Company-facing executive for Item 9 Labs Corp. Michael Keskey has resigned as Chief Legal Officer.
공시 • May 23+ 1 more updateItem 9 Labs Corp. Announces CEO ChangesItem 9 Labs Corp. announced that on May 17, 2023, Mr. Michael Weinberger voluntarily resigned as Chief Executive Officer and member of the Board of Directors of the Company. On May 22, 2023, the Board appointed Mr. Douglas Bowden, age 63, as the Company’s Interim Chief Executive Officer. Mr. Bowden is currently the Chairman of the Company’s Board of Directors. The biography for Mr. Bowden is set forth below: Mr. Bowden started his career in the electronics industry, working in a successful family run business, which he purchased with his brother and ran for nearly 20 years. This tech company's success was based on signal processing and monitoring providing hardware and software for broadcasters during the high definition revolution. Bowden sold his business in 2009 and in 2013, Mr. Bowden and his son started Viridis Group, a real estate company centered on residential remodeling, multifamily and commercial real estate development in Colorado and Arizona. Through this venture they gained experience in real estate acquisition, design, project and construction management, leasing, finance and sales. Viridis Group has recently adopted the name Bowden Investment Group. Mr. Bowden attended the University of South Dakota where he studied business. Mr. Bowden is co-founder of Viridis Group, dba Bowden Investment Group, a strategic partner of the Company.
공시 • May 16Item 9 Labs Corp. announced delayed 10-Q filingOn 05/15/2023, Item 9 Labs Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 11Item 9 Labs Releases Latest Limited Edition One-Gram Rosin-Infused Pre-RollsItem 9 Labs announced the latest release of its limited edition one-gram rosin-infused pre-rolls in participating Arizona dispensaries. The product release follows a successful initial test run in December 2022 that immediately sold out after being stocked in local dispensaries and generated extremely positive customer and budtender feedback on the product quality. The demand for solventless cannabis products in Arizona has continued to grow since the start of the state's adult-use cannabis market, especially in the concentrate and vape categories. The niche sector provides a consistent, high quality and fuller expression of the various cannabinoids and terpenes that the cannabis plant has to offer. Cannabis data firm BDSA analyzed product data from the past year and noted that the growing rosin category is making a significant mark among many mature markets in the evolving industry, counting single to double-digit growth in sales from 2021 to 2022. Item 9 Labs' addition of rosin-infused pre therolls bolsters its already extensive product lineup of connoisseur grade pre-rolls, featuring one-gram pre-rolls crafted with its award-winning flower and infused with live resin sugar, live resin badder or crumble concentrates. According to BDSA's most recent market research, Item 9 Labs ranked No. 3 in Arizona's one-gram infused pre-roll category for February 2023, capturing 8.5% market share. Overall, the state generated $4.16 million in infused pre-rolls that month. Being sold in over 65% of Arizona's dispensaries, Item 9 Labs is recognized as one of the top 10 leading cannabis brands in the state. The rosin-infused pre -infused pre-rolls are sold at participating Botanica, JARS and Nature's Medicines locations, among other dispensaries throughout Phoenix.
공시 • Dec 30Item 9 Labs Corp. announced delayed annual 10-K filingOn 12/29/2022, Item 9 Labs Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Dec 09Item 9 Labs Corp. Announces Management PromotionsItem 9 Labs Corp. announced promotion of Mark Busch, Senior Vice President of Corporate Development, Cory Carter, Senior Vice President of Cultivation and Jayne Levy Senior Vice President of Communications. Mark Busch is One of the first hires on the Unity Rd. brand, Busch joined in 2018, pre-dating Item 9 Labs Corp.'s acquisition of Unity Rd.'s franchisor, OCG Inc. in 2021. He is responsible for overseeing merger and acquisition strategy and activities. He has led the team through acquisitions of multiple dispensaries and most recently, has been spearheading the Company's approaching acquisition of Sessions. Carter joined OCG Inc. in 2019 and took over all Item 9 Labs Corp. cultivation operations upon acquisition close. He is lead on all production, manufacturing and packaging of the Company's award-winning Item 9 Labs cannabis products, including managing a team of 50-plus and aiding in the continued development of the Company's cultivation and lab site in Coolidge, Ariz. Levy has been with Unity Rd. since the cannabis franchise's inception in 2018. She plays an integral role in the Company with a hand in all facets of communications – spearheading internal and corporate communications, investor relations, public relations and beyond.
공시 • Dec 01+ 1 more updateItem 9 Labs Corp. Announces Resignation of Andrew Bowden as DirectorOn November 23, 2022, Mr. Andrew Bowden voluntarily resigned as Chief Executive Officer and member of the Board of Directors of Item 9 Labs Corp. The resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. The Company is appreciative of Mr. Bowden’s years of service to the Company as a director and Chief Executive Officer.
공시 • Aug 04Item 9 Labs Corp. to Report Q3, 2022 Results on Aug 15, 2022Item 9 Labs Corp. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 15, 2022
공시 • Jun 05Item 9 Labs Corp Announces Resignation of Jeffrey Rassas as the Chief Strategy OfficerOn June 1, 2022, Mr. Jeffrey Rassas resigned, effective immediately, as the Chief Strategy Officer of Item 9 Labs Corp. (the Company") and the Company's management accepted Mr. Rassas' resignation on June 1, 2022. Mr. Rassas' resignation was not due to any disagreement with the Company on any matter relating to the Company's operations, policies, practices, or otherwise. Mr. Rassas will remain on the Company's board of directors and will continue working with the Company in a consulting role.
공시 • May 26Item 9 Labs Corp. (OTCPK:INLB) signed a definitive agreement to acquire Sessions Cannabis from Steven Fry, Najla Guthrie, Darryl Allen, Louis Laskovski, 2628146 Ontario Ltd. and 11949896 Canada Inc. for $21 million.Item 9 Labs Corp. (OTCPK:INLB) signed a definitive agreement to acquire Sessions Cannabis from Steven Fry, Najla Guthrie, Darryl Allen, Louis Laskovski, 2628146 Ontario Ltd. and 11949896 Canada Inc. for $21 million on May 18, 2022. As per the terms of the transaction, Item 9 Labs shall pay $12.8 million plus the earnout payments of $4.1 million of common stock 12 months following the closing date and $4.1 million common stock 24 months following the closing date subject to post-closing adjustments. Item 9 Labs Corp. shall pay a termination fee of $0.54 million to the sellers. The transaction is subject to customary closing conditions including Item 9 Labs receiving financing sufficient to complete the transaction and Sessions Cannabis shall have a minimum cash balance of $0.1 million. Frank Robinson and Jeffrey Mikelberg of Cassels Brock & Blackwell LLP acted as legal advisors to the sellers and Francesco Gucciardo and Gary Volman of Aird & Berlis LLP acted as legal advisor to Item 9 Labs Corp.
공시 • Mar 06Item 9 Labs Corp. (OTCPK:INLB) acquired Certain Assets from Nebrina Adams County LLC.Item 9 Labs Corp. (OTCPK:INLB) agreed to acquire Certain Assets of Nebrina Adams County LLC for $2 million on October 6, 2021. The total purchase price will be payable as follows: (i) Upon conditional approvals of the change of ownership from state and local licensing authorities concerning the transfer of ownership of the Licenses from Seller to Buyer, Buyer shall deposit into an escrow account One Million US Dollars. ii) At the Closing, Buyer and Company shall execute and deliver to Seller an unsecured promissory note with a principal amount of Two Hundred Thousand US Dollars ($200,000.00), with an interest rate of five percent (5%) per annum simple interest, for a term of eighteen (18) full months commencing on the Closing Date, and payable in six (6) installments commencing on the last day of each three (3) month period following the Closing Date (the " Note " or " Promissory Note" ) until paid in full; and (iii) Buyer shall issue to the Seller Three Hundred Thousand (300,000) shares of PubCo's restricted common shares of the Company. The Shares shall be subject to a leak out agreement. Closing shall be contingent upon the unconditional approval by MED and the Local Licensing Authority of the Transactions. Jean Gonnell of Gonnell Law acted as legal advisor to Nebrina. Zuber Lawler & Del Duca LLP acted as legal advisor to Item 9. Item 9 Labs Corp. (OTCPK:INLB) acquired Certain Assets from Nebrina Adams County LLC on March 4, 2022.
공시 • Mar 04Item 9 Labs Corp. Appoints Shane Evans to Its Board of DirectorsItem 9 Labs Corp. announced that Shane Evans, founder of Massage Heights, has been appointed to its Board of Directors.
공시 • Feb 03Item 9 Labs Corp. Announces Resignation of Ronald L. Miller, Jr. from the Board of DirectorsOn January 25, 2022, Mr. Ronald L. Miller, Jr. resigned, effective immediately, from the board of directors of Item 9 Labs Corp. and the board accepted Mr. Miller’s resignation on January 26, 2022. Mr. Miller’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies, practices, or otherwise. The Company is appreciative of Mr. Miller’s decade of service to the Company as a director. Mr. Miller will continue working with the Company in a financial consulting role.
공시 • Dec 31Item 9 Labs Corp. announced delayed annual 10-K filingOn 12/30/2021, Item 9 Labs Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Dec 30Item 9 Labs Corp. announced delayed annual 10-K filingOn 12/29/2020, Item 9 Labs Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Sep 26Item 9 Labs Corp. (OTCPK:INLB) entered into an agreement to acquire OCG Inc. for $36.6 million.Item 9 Labs Corp. (OTCPK:INLB) entered into an agreement to acquire OCG Inc. for $36.6 million on February 27, 2020. Under the terms of the transaction, Item 9 Labs Corp. will issue 30 million restricted shares as consideration to acquire 52.22 million shares of OCG Inc. resulting in an exchange ratio of 0.575 shares of Item 9 Labs Corp. for each share of OCG Inc. Upon closing, OCG Inc. will become a wholly-owned direct subsidiary of Item 9 Labs Corp. Upon closing of the transaction, OCG Inc. may nominate, and Item 9 Labs Corp. agrees to appoint, two persons designated by OCG Inc. to Item 9 Labs Corp.’s Board of Directors. The transaction is subject to the adoption of the agreement by the requisite vote of the stockholders of OCG Inc. and Item 9 Labs Corp., approval of the issuance of shares of Item 9 Labs Corp. as merger consideration, an appropriate level and Director and Officers Liability Insurance being in place, financing contingency that Item 9 Labs Corp. must raise approximately $2 million and delivery by OCG Inc. of copies of a lock up and leak out agreement. The Board of Directors of Item 9 Labs Corp. has approved the agreement and the transactions contemplated hereby. The transaction is expected to closing in early July 2020. The transaction is expected to close near the Item 9 Labs’s fiscal year end of September 30, 2020. Michael Weiner and David Mangum of Dorsey & Whitney LLP acted as legal advisors for OCG, Inc. Jessica M. Lockett of Horwitz +Armstrong acted as legal advisor for Item 9 Labs Corp.